vs
STANDARD BIOTOOLS INC.(LAB)与UNITY BANCORP INC(UNTY)财务数据对比。点击上方公司名可切换其他公司
UNITY BANCORP INC的季度营收约是STANDARD BIOTOOLS INC.的1.8倍($35.3M vs $19.6M),UNITY BANCORP INC净利率更高(43.9% vs -177.4%,领先221.3%),UNITY BANCORP INC同比增速更快(24.2% vs -11.5%),UNITY BANCORP INC自由现金流更多($44.3M vs $-23.1M),过去两年UNITY BANCORP INC的营收复合增速更高(17.5% vs -12.2%)
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
Unity Bancorp Inc是总部位于美国新泽西州的金融控股公司,旗下运营Unity Bank,面向新泽西州及宾夕法尼亚州东部的本地社区,提供商业贷款、存款账户、抵押贷款、个人银行等全系列商业及零售银行服务,核心服务客群为中小企业和个人消费者。
LAB vs UNTY — 直观对比
营收规模更大
UNTY
是对方的1.8倍
$19.6M
营收增速更快
UNTY
高出35.6%
-11.5%
净利率更高
UNTY
高出221.3%
-177.4%
自由现金流更多
UNTY
多$67.4M
$-23.1M
两年增速更快
UNTY
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $19.6M | $35.3M |
| 净利润 | $-34.7M | $15.5M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 55.8% |
| 净利率 | -177.4% | 43.9% |
| 营收同比 | -11.5% | 24.2% |
| 净利润同比 | -28.8% | 34.5% |
| 每股收益(稀释后) | $-0.09 | $1.52 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
LAB
UNTY
| Q4 25 | — | $35.3M | ||
| Q3 25 | $19.6M | $32.8M | ||
| Q2 25 | $21.8M | $34.4M | ||
| Q1 25 | $40.8M | $29.4M | ||
| Q4 24 | — | $28.4M | ||
| Q3 24 | $22.1M | $27.7M | ||
| Q2 24 | $22.5M | $25.5M | ||
| Q1 24 | $45.5M | $25.6M |
净利润
LAB
UNTY
| Q4 25 | — | $15.5M | ||
| Q3 25 | $-34.7M | $14.4M | ||
| Q2 25 | $-33.5M | $16.5M | ||
| Q1 25 | $-26.0M | $11.6M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $-26.9M | $10.9M | ||
| Q2 24 | $-45.7M | $9.5M | ||
| Q1 24 | $-32.2M | $9.6M |
毛利率
LAB
UNTY
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率
LAB
UNTY
| Q4 25 | — | 55.8% | ||
| Q3 25 | -168.5% | 57.5% | ||
| Q2 25 | -118.1% | 62.6% | ||
| Q1 25 | -80.8% | 52.6% | ||
| Q4 24 | — | 51.0% | ||
| Q3 24 | -120.9% | 52.7% | ||
| Q2 24 | -134.5% | 49.3% | ||
| Q1 24 | -132.2% | 50.0% |
净利率
LAB
UNTY
| Q4 25 | — | 43.9% | ||
| Q3 25 | -177.4% | 43.8% | ||
| Q2 25 | -153.7% | 48.0% | ||
| Q1 25 | -63.8% | 39.5% | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | -122.0% | 39.4% | ||
| Q2 24 | -203.3% | 37.1% | ||
| Q1 24 | -70.6% | 37.5% |
每股收益(稀释后)
LAB
UNTY
| Q4 25 | — | $1.52 | ||
| Q3 25 | $-0.09 | $1.41 | ||
| Q2 25 | $-0.09 | $1.61 | ||
| Q1 25 | $-0.07 | $1.13 | ||
| Q4 24 | — | $1.13 | ||
| Q3 24 | $-0.07 | $1.07 | ||
| Q2 24 | $-0.12 | $0.92 | ||
| Q1 24 | $-0.27 | $0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $345.6M |
| 总资产 | $539.6M | $3.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
LAB
UNTY
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务
LAB
UNTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $230.8M | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益
LAB
UNTY
| Q4 25 | — | $345.6M | ||
| Q3 25 | $399.7M | $334.0M | ||
| Q2 25 | $424.5M | $319.8M | ||
| Q1 25 | $454.6M | $306.1M | ||
| Q4 24 | — | $295.6M | ||
| Q3 24 | $489.3M | $284.3M | ||
| Q2 24 | $510.3M | $273.4M | ||
| Q1 24 | $577.3M | $266.8M |
总资产
LAB
UNTY
| Q4 25 | — | $3.0B | ||
| Q3 25 | $539.6M | $2.9B | ||
| Q2 25 | $557.0M | $2.9B | ||
| Q1 25 | $579.6M | $2.8B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $681.5M | $2.6B | ||
| Q2 24 | $708.7M | $2.6B | ||
| Q1 24 | $777.7M | $2.6B |
负债/权益比
LAB
UNTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $44.9M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $44.3M |
| 自由现金流率自由现金流/营收 | -118.1% | 125.7% |
| 资本支出强度资本支出/营收 | 4.5% | 1.6% |
| 现金转化率经营现金流/净利润 | — | 2.90× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $81.7M |
8季度趋势,按日历期对齐
经营现金流
LAB
UNTY
| Q4 25 | — | $44.9M | ||
| Q3 25 | $-22.2M | $45.5M | ||
| Q2 25 | $-20.7M | $-25.3M | ||
| Q1 25 | $-30.3M | $17.9M | ||
| Q4 24 | — | $48.0M | ||
| Q3 24 | $-27.9M | $17.7M | ||
| Q2 24 | $-39.0M | $-8.4M | ||
| Q1 24 | $-62.5M | $15.8M |
自由现金流
LAB
UNTY
| Q4 25 | — | $44.3M | ||
| Q3 25 | $-23.1M | $45.3M | ||
| Q2 25 | $-22.6M | $-25.5M | ||
| Q1 25 | $-35.3M | $17.6M | ||
| Q4 24 | — | $47.3M | ||
| Q3 24 | $-30.1M | $17.5M | ||
| Q2 24 | $-41.0M | $-8.6M | ||
| Q1 24 | $-63.3M | $15.7M |
自由现金流率
LAB
UNTY
| Q4 25 | — | 125.7% | ||
| Q3 25 | -118.1% | 138.1% | ||
| Q2 25 | -103.6% | -74.2% | ||
| Q1 25 | -86.6% | 59.9% | ||
| Q4 24 | — | 166.5% | ||
| Q3 24 | -136.4% | 63.3% | ||
| Q2 24 | -182.2% | -33.7% | ||
| Q1 24 | -138.9% | 61.4% |
资本支出强度
LAB
UNTY
| Q4 25 | — | 1.6% | ||
| Q3 25 | 4.5% | 0.7% | ||
| Q2 25 | 8.7% | 0.5% | ||
| Q1 25 | 12.4% | 1.0% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 10.2% | 0.5% | ||
| Q2 24 | 8.6% | 0.5% | ||
| Q1 24 | 1.7% | 0.3% |
现金转化率
LAB
UNTY
| Q4 25 | — | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 4.17× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | 1.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
UNTY
暂无分部数据